The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Luca Durelli

Division of Neurology

San Luigi Gonzaga University Hospital

Regione Gonzole

10, I 100143 Orbassano

Italy

[email]@unito.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Neurology, San Luigi Gonzaga University Hospital, Regione Gonzole, 10, I 100143 Orbassano, Italy. 2004 - 2009
  • Dipartimento di Scienze Cliniche, e Biologiche, Universita' di Torino, Divisione di Neurologia, Italy. 2008
  • Department of Neuroscience, University of Turin, Turin, Italy. 2003 - 2004
  • Clinica Neurologica I, Dipartimento di Neuroscienze, Universita' di Torino, Italy. 1999 - 2001

References

  1. Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b. Durelli, L., Barbero, P., Cucci, A., Ferrero, B., Ricci, A., Contessa, G., De Mercanti, S., Ripellino, P., Lapuma, D., Viglietta, E., Bergui, M., Versino, E., Clerico, M. Expert. Opin. Biol. Ther (2009) [Pubmed]
  2. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders. Durelli, L., Barbero, P., Bergui, M., Versino, E., Bassano, M.A., Verdun, E., Ferrero, B., Rivoiro, C., Ferrero, C., Picco, E., Ripellino, P., Viglietti, D., Giuliani, G., Montanari, E., Clerico, M. J. Neurol. (2008) [Pubmed]
  3. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. Durelli, L., Barbero, P., Bergui, M., Versino, E., Bassano, M.A., Verdun, E., Rivoiro, C., Ferrero, C., Picco, E., Ripellino, P., Giuliani, G., Montanari, E., Clerico, M. J. Neurol. Neurosurg. Psychiatr. (2008) [Pubmed]
  4. Anti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy. Durelli, L., Ricci, A. Front. Biosci. (2004) [Pubmed]
  5. Is multiple sclerosis a disease that requires frequent beta interferon dosing?. Durelli, L. J. Neurol. (2004) [Pubmed]
  6. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS. Durelli, L. J. Neurol. (2003) [Pubmed]
  7. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study. Durelli, L., Ferrero, B., Oggero, A., Verdun, E., Ghezzi, A., Montanari, E., Zaffaroni, M. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  8. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Durelli, L., Ferrero, B., Oggero, A., Verdun, E., Ghezzi, A., Montanari, E., Zaffaroni, M. Neurology (2001) [Pubmed]
  9. Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study. Durelli, L., Oggero, A., Verdun, E., Isoardo, G.L., Barbero, P., Bergamasco, B., Brossa, P.C., Ghigo, E., Maccario, M., Faggiano, F. J. Neurol. Sci. (2001) [Pubmed]
  10. Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?. Durelli, L., Oggero, A., Verdun, E., Isoardo, G., Ricci, A., Barbero, P., Bergamasco, B. J. Neurol. Sci. (2000) [Pubmed]
  11. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. Durelli, L., Ferrero, B., Oggero, A., Verdun, E., Bongioanni, M.R., Gentile, E., Isoardo, G.L., Ricci, A., Rota, E., Bergamasco, B., Durazzo, M., Saracco, G., Biava, M.A., Brossa, P.C., Giorda, L., Pagni, R., Aimo, G. J. Neurol. Sci. (1999) [Pubmed]
 
WikiGenes - Universities